Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation-Reference-Cited by-同舟云学术

Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation

Published:2021-12-01 Issue:12 Volume:44 Page:1819-1823
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Saito Yoshitaka¹,Takekuma Yoh¹,Komatsu Yoshito²,Sugawara Mitsuru³

Affiliation:

1. Department of Pharmacy, Hokkaido University Hospital

2. Cancer Center, Hokkaido University Hospital

3. Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/44/12/44_b21-00653/_pdf

Reference18 articles.

1. 1) Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res., 12, 6243s–6249s (2006).

2. 2) Hird A, Zhang L, Holt T, Fairchild A, DeAngelis C, Loblaw A, Wong R, Barnes E, Tsao M, Danjoux C, Chow E. Dexamethasone for the prophylaxis of radiation-induced pain flare after palliative radiotherapy for symptomatic bone metastases: a phase II study. Clin. Oncol. (R. Coll. Radiol.), 21, 329–335 (2009).

3. 3) Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 377, 813–822 (2011).

4. 4) Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Damião R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur. J. Cancer, 51, 1812–1821 (2015).

5. 5) Nasser SM, Sahal A, Hamad A, Elazzazy S. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: a retrospective cohort study. J. Oncol. Pharm. Pract., 25, 1846–1852 (2019).

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence and predictors of hypocalcemia in end-stage renal disease patients on denosumab therapy: A systematic review and meta-analysis;World Journal of Meta-Analysis;2024-09-18

2. External Validation and Update of the Risk Prediction Model for Denosumab-Induced Hypocalcemia Developed From a Hospital-Based Administrative Database;JCO Clinical Cancer Informatics;2024-07

3. Severe hypocalcemia after denosumab treatment leading to refractory ventricular tachycardia and veno-arterial extracorporeal membrane oxygenation support: a case report;International Journal of Emergency Medicine;2023-08-28

4. Effects of anti-RANKL antibodies administered to pregnant mice on bone and tooth development in neonates;Journal of Oral Biosciences;2023-06

5. Integrated Osteoporosis Care to Reduce Denosumab-Associated Hypocalcemia for Patients with Advanced Chronic Kidney Disease and End-Stage Renal Disease;Healthcare;2023-01-20